It’s been a busy year at Insulet (NSDQ:PODD).
The diabetes tech company welcomed a new CEO, launched its first new product in six years and officially opened its $200 million global headquarters – all in the first half of 2019.
That’s all the result of years of rapid growth for Insulet, chief executive Shacey Petrovic said in a keynote interview at DeviceTalks Boston this month. The company’s customer base has doubled in the last four years to roughly 150,000 ‘Podders’ – the self-selected name for people who use Insulet’s tubeless, wearable insulin delivery device, the Omnipod.
Omnipod Dash, the newest iteration of Insulet’s device, is the company’s latest attempt at making the lives of people living with diabetes simpler, according to Petrovic.
“Something common across all people living with diabetes – and all families because it’s very much a family disease – is the need to reduce burden and to simplify life,” Petrovic told attendees at DeviceTalks Boston 2019.